Last reviewed · How we verify
Insulin glargine U100 — Competitive Intelligence Brief
marketed
Long-acting basal insulin
Insulin receptor
Diabetes
Small molecule
Live · refreshed every 30 min
Target snapshot
Insulin glargine U100 (Insulin glargine U100) — Novo Nordisk A/S. Insulin glargine is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and reduce blood glucose levels.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin glargine U100 TARGET | Insulin glargine U100 | Novo Nordisk A/S | marketed | Long-acting basal insulin | Insulin receptor | |
| Tresiba | INSULIN DEGLUDEC | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2015-01-01 |
| Levemir | INSULIN DETEMIR | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2005-01-01 |
| Apidra | INSULIN GLULISINE | Sanofi | marketed | Insulin Analog [EPC] | Insulin receptor | 2004-01-01 |
| Novolog | INSULIN ASPART | Novo Nordisk | marketed | Insulin Analog [EPC] | Insulin receptor | 2000-01-01 |
| Lantus | INSULIN GLARGINE | Sanofi | marketed | Insulin Analog [EPC] | Insulin receptor | 2000-01-01 |
| Humalog | INSULIN LISPRO | Eli Lilly | marketed | Insulin Analog [EPC] | Insulin receptor | 1996-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Long-acting basal insulin class)
- Sanofi · 12 drugs in this class
- Novo Nordisk A/S · 3 drugs in this class
- Life for a Child Program, Diabetes Australia · 1 drug in this class
- Massachusetts General Hospital · 1 drug in this class
- Merck Sharp & Dohme LLC · 1 drug in this class
- Providence Health & Services · 1 drug in this class
- Rabin Medical Center · 1 drug in this class
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud · 1 drug in this class
- University Hospital Tuebingen · 1 drug in this class
- Gan and Lee Pharmaceuticals, USA · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin glargine U100 CI watch — RSS
- Insulin glargine U100 CI watch — Atom
- Insulin glargine U100 CI watch — JSON
- Insulin glargine U100 alone — RSS
- Whole Long-acting basal insulin class — RSS
Cite this brief
Drug Landscape (2026). Insulin glargine U100 — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-u100. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab